COMMUNIQUÉS West-GlobeNewswire

Peptinovo Biopharma in Collaboration with Chemelectiva Announces Breakthrough Manufacturing Innovation for Targeted Chemotherapy
17/12/2025
First-of-its-kind semi-synthetic vitamin E product enables scalable, FDA-compliant production of Peptinovo’s proprietary cancer prodrugs ANN ARBOR, Mich., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Peptinovo Biopharma, an Ann [...]
Kohope Medical Devices Announces 40% Production Capacity Increase and New Distribution Center to Serve North American Market
17/12/2025
Shanghai Kohope Medical Devices Co., Ltd. invests $2.5 million in facility expansion hub to meet surging demand for syringes and medical needles across United States and Canada. SHANGHAI, Dec. 17, 2025 (GLOBE NEWSWIRE [...]
Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients
17/12/2025
Ratutrelvir shows a differentiated profile versus PAXLOVID™ with fewer adverse events and no viral rebounds Activity shown in Paxlovid ® -ineligible patients, representing a significant population with few effective [...]
Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress
17/12/2025
-- Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA -- -- Incremental weight loss is an acceptable approvable [...]
Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease
17/12/2025
NESS ZIONA, Israel, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today provided an update [...]
4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease
17/12/2025
Clinically meaningful lung function activity, measured by ppFEV 1 and LCI 2.5 , with follow-up through 1 year at dose selected for Phase 2 Durable CFTR transgene expression within target therapeutic range with follow-up [...]
Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference
17/12/2025
ALACHUA, Fla. and TAMPA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, [...]
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference
17/12/2025
SAN CARLOS, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that Mick Hitchcock, Ph.D., Interim Chief Executive [...]
Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program
17/12/2025
License Agreement grants Sagimet a global, exclusive license to innovative forms of resmetirom active pharmaceutical ingredient (API) developed by TAPI and covered by TAPI patent applications Collaboration supports [...]
Secura Bio Announces NCCN® Duvelisib (COPIKTRA®) Update to Clinical Practice Guidelines in Oncology for Cutaneous T-Cell Lymphoma (CTCL), Including Mycosis Fungoides and Sézary Syndrome
17/12/2025
BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. ( www.securabio.com ), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced that [...]
EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference
17/12/2025
WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal [...]
Addition Therapeutics Announces $100 Million in Funding and Significant Progress Advancing Mission to Fulfill Promise of Genomic Medicine for Chronic and Rare Diseases
17/12/2025
All-RNA, non-viral, LNP-based PRINT™ platform is designed to develop safer, durable, one-time therapies for a broad range of unmet needs Addition is advancing a robust pipeline of PRINTed therapeutics for chronic and [...]
Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference
17/12/2025
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to deliver a [...]
Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
17/12/2025
FRIENDSWOOD, Texas, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the largest [...]
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
17/12/2025
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that Dipal Doshi, Chief Executive Officer, will deliver a company presentation at the 44 th Annual J.P. Morgan [...]
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
17/12/2025
The study is designed to evaluate the safety and clinical activity of NXP900 in combination with osimertinib in patients with epidermal growth factor receptor mutated (EGFR mut+) non-small cell lung cancer (NSCLC) whose [...]
Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer
17/12/2025
Agreement Calls for Development Services and Tech Transfer in Preparation for Commercial Manufacturing of Injectable Pharmaceutical Product Partner’s Program Size Positions it to Become a Top Five Commercial Customer [...]
CMR Surgical secures 510(k) clearance of its Versius Plus robotic surgical system
17/12/2025
16 December 2025 CMR Surgical secures 510(k) clearance of its Versius Plus robotic surgical system Regulatory clearance of CMR’s most advanced system paves the way for upcoming US commercial launch Strong clinical [...]
Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers
17/12/2025
Preliminary Phase 1b data is in line with Phase 1a data reported at the European Society of Medical Oncology in September 2025 Combined disease control rate of 90% across both Phase 1a and Phase 1b patients with [...]

Pages